secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2024-09-11T23:59:59+00:00
Accession:  0001753926-24-001565
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Lipella shareholders approve reverse stock split authorization at annual meeting
--------------------------------------------------------------------------------

- All seven director nominees elected (including CEO Jonathan Kaufman); broker non-votes of 1,703,278.
- Reverse stock split authorized (3,881,533 for, 407,381 against); board may implement up to 1:150 within one year.
- Ratification of auditor Urish Popeck & Co. for FY2024 ratified with 4,232,289 votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392624001565/0001753926-24-001565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392624001565/g084428_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer